Section Arrow
LBRX.NASDAQ
- LB Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/02/19 13:47 EST
Regular Hours
Last
 24.12
+0.1 (+0.42%)
Day High 
24.2 
Prev. Close
24.02 
1-M High
24.9499 
Volume 
46.09K 
Bid
24.12
Ask
24.29
Day Low
22.9 
Open
23.93 
1-M Low
19.385 
Market Cap 
607.68M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.7 
20-SMA 22.99 
50-SMA 21.64 
52-W High 24.9499 
52-W Low 13.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/-3.72
Enterprise Value
610.90M
Balance Sheet
Book Value Per Share
12.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2068+0.0148+7.71%0.09PE
IBRXImmunityBio8.42-0.12-1.41%-- 
DRMADermata Therapeutics Inc2.055+0.775+60.55%0.08PE
GERNGeron Corp1.875-0.065-3.35%-- 
ENVBEnveric Biosciences Inc.2.3201+0.0801+3.58%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broadtherapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.